BMY - Bristol Myers Squibb's Acquired Adagrasib Combo Therapy May Benefit Colorectal Cancer Patients With Certain Mutation | Benzinga
Monday, Bristol Myers Squibb & Co (NYSE:BMY) released data from the cohorts of the Phase 1/ 2 KRYSTAL-1 study evaluating Krazati (adagrasib) in combination with cetuximab for previously treated KRASG12C-mutated locally advanced or metastatic colorectal cancer.
With a median follow-up of 11.9 months in 94 patients, Krazati plus cetuximab demonstrated an objective response rate, the primary endpoint, of 34%, median progression-free survival of 6.9 months, and median overall survival of 15.9 months.